CD274 and non-small cell lung carcinoma: Immunotherapy-radiomics prediction vector (IRPV) could predict PD-L1 positivity in NSCLC testing cohort (AUC = 0.7, 95% CI: 0.57-0.84). IRPV could also stratify patients into a high- and low-risk survival group (HR= 2.26, 95% CI: 1.21-4.24, p = 0.011 and HR = 2.45, 95% CI: 1.07-5.65, p = 0.035).